| 000 | 01668 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515161050.0 | ||
| 264 | 0 | _c20090515 | |
| 008 | 200905s 0 0 eng d | ||
| 022 | _a1521-7035 | ||
| 024 | 7 |
_a10.1016/j.clim.2009.01.005 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLoftus, B | |
| 245 | 0 | 0 |
_aAutologous attenuated T-cell vaccine (Tovaxin) dose escalation in multiple sclerosis relapsing-remitting and secondary progressive patients nonresponsive to approved immunomodulatory therapies. _h[electronic resource] |
| 260 |
_bClinical immunology (Orlando, Fla.) _cMay 2009 |
||
| 300 |
_a202-15 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xadverse effects |
| 650 | 0 | 4 |
_aImmunotherapy _xstandards |
| 650 | 0 | 4 | _aInfusions, Subcutaneous |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdrug therapy |
| 650 | 0 | 4 |
_aMyelin Basic Protein _xgenetics |
| 650 | 0 | 4 |
_aT-Lymphocytes _ximmunology |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aVaccines |
| 650 | 0 | 4 |
_aVaccines, Attenuated _xtherapeutic use |
| 650 | 0 | 4 |
_aVaccines, Subunit _xadverse effects |
| 700 | 1 | _aNewsom, B | |
| 700 | 1 | _aMontgomery, M | |
| 700 | 1 | _aVon Gynz-Rekowski, K | |
| 700 | 1 | _aRiser, M | |
| 700 | 1 | _aInman, S | |
| 700 | 1 | _aGarces, P | |
| 700 | 1 | _aRill, D | |
| 700 | 1 | _aZhang, J | |
| 700 | 1 | _aWilliams, J C | |
| 773 | 0 |
_tClinical immunology (Orlando, Fla.) _gvol. 131 _gno. 2 _gp. 202-15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clim.2009.01.005 _zAvailable from publisher's website |
| 999 |
_c18673254 _d18673254 |
||